Advertisement

Topics

Lonza to manufacture Alector’s mAb drug candidates for Ph I trial

11:49 EDT 9 May 2019 | Outsourcing-Pharma

Lonza will provide manufacturing for Alectorâs Phase I drug candidates for neurodegenerative diseases form its Switzerland site, which is expected to be operational by mid-2020.

Original Article: Lonza to manufacture Alector’s mAb drug candidates for Ph I trial

NEXT ARTICLE

More From BioPortfolio on "Lonza to manufacture Alector’s mAb drug candidates for Ph I trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...